Zanubrutinib plus CAR-T for Richter syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Richter syndrome (DLBCL) that happened with or after CLL/SLL
- Your disease is relapsed or refractory, or Richter syndrome started while you were on CLL treatment
- You’re age 18 or older and can do study visits with an ECOG performance status of 0–2
- Your blood counts and organ blood tests meet thresholds (including adequate kidney, liver, and heart function)
- You must be able to safely receive CAR-T at the treating center (including swallowing pills and consent ability)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Hear when a new Recurrent Transformed Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.